Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Idera Pharmaceuticals has reported that Robert Karr, president of the company, has resigned from his full-time management position at the company, effective December 31, 2007.
Subscribe to our email newsletter
Mr. Karr has entered into a consulting agreement with the company and will remain a member of the company’s board of directors.
Mr. Karr said: “I am proud of the tremendous accomplishments Idera has made in the discovery and development of TLR-targeted therapeutics highlighted by the recent announcement of our oncology collaboration with Merck KGaA.”